Cytisinicline and the FDA: what a Complete Response Letter actually means
Cytisinicline is not FDA-approved as a smoking-cessation aid in the United States: on June 22, 2026, Achieve Life Sciences announced it received a Complete Response Letter from the FDA for its cytisinicline application, citing manufacturing-facility and labeling issues rather than any concern about efficacy or safety.
Cytisinicline does not currently have FDA approval. This page reflects the situation as of that date and will be updated when the company resubmits its application.
On June 22, 2026, Achieve Life Sciences announced that it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration for its New Drug Application for cytisinicline. A Complete Response Letter means the FDA reviewed the application and decided it cannot approve it in its current form. That is the entire, correct summary of where things stand: cytisinicline is not FDA-approved right now.
What the FDA actually cited
According to the company's press release, the CRL was not about the drug's clinical results. The FDA raised two issues, both administrative rather than clinical:
-
ManufacturingObservations from a cGMP inspection of a third-party facilityThe facility received an "Official Action Indicated" (OAI) classification for general compliance matters unrelated to cytisinicline itself — meaning the issues flagged were about that facility's broader manufacturing practices, not something specific to this drug.
-
LabelingFinal product labeling was not completed by the FDA's action dateThe labeling review simply wasn't finished in time. Incomplete labeling at the action date is on its own a common basis for a Complete Response Letter.
The company's press release is explicit on the point that matters most to anyone evaluating whether this drug works:
"The FDA identified no deficiencies regarding the clinical efficacy or safety of cytisinicline."
That single line is the important distinction to hold onto. A CRL is not a rejection of a drug's effectiveness or a safety finding against it — it's the FDA saying an application isn't ready to approve yet, for whatever reason, and here the reasons given were about a manufacturing facility's general compliance status and unfinished labeling paperwork, not about whether cytisinicline works or is safe.
What a Complete Response Letter is — and isn't
| A CRL is | A CRL is not |
|---|---|
| The FDA's formal notice that an application can't be approved as submitted | A final "no" — companies routinely resubmit and gain approval later |
| Sometimes about manufacturing, labeling, or other administrative gaps | Necessarily a statement about whether the drug is effective or safe |
| A normal, fairly common part of the FDA review process | Unique to this drug or this company |
What cytisinicline is, at a high level
Cytisinicline is a plant-derived compound that has been used in some countries as a smoking-cessation aid for a long time. It's related to, but chemically and developmentally distinct from, varenicline (marketed elsewhere as Chantix/Champix) — both act on the same general class of nicotinic receptors, but they are not the same molecule and have gone through separate regulatory histories. We're intentionally not stating efficacy percentages, trial names, dosing regimens, or approval status outside the US here, because those details go beyond what's been verified for this page — if you want that level of detail, read the primary source directly.
What happens next
Achieve Life Sciences has stated it intends to resubmit the NDA in Q4 2026, naming Adare as its primary manufacturing partner, with the company citing potential FDA approval in the first half of 2027, to be followed by a US commercial launch if that approval is granted. Those are the company's own stated plans and timeline, not a guarantee — resubmission timelines and approval outcomes can shift.
Source: Achieve Life Sciences press release, June 22, 2026.
What to do while you wait
If you were watching cytisinicline as a future quit-smoking option, there's no need to put quitting on hold until it's approved. Options that exist today, none of which require waiting on any pending drug application:
Ask about nicotine replacement therapy (patches, gum, lozenges) or other prescription options already approved and available now. A doctor can help you weigh what fits your history and health.
In the US, 1-800-QUIT-NOW connects you to free coaching through your state's quit-smoking service. It costs nothing and it's staffed by people trained specifically for this.
Some people quit by stopping outright; many do better with a gradual, planned reduction toward a chosen quit date. That's the approach NOPE is built around: a daily cigarette allowance that steps down to zero, logged honestly, with a guided-breathing tool for the moments a craving hits hardest. It's behavioral support, not a medical treatment, and it doesn't replace anything a doctor might prescribe — it's simply available today, independent of any pending drug's regulatory status.
The FDA does not publish Complete Response Letters. Everything on this page therefore reflects Achieve Life Sciences' own characterisation of what the letter said, as given in its press release — not an independent reading of the letter itself.
Common questions
Is cytisinicline FDA-approved?
No. As of this writing, cytisinicline is not FDA-approved. On June 22, 2026, Achieve Life Sciences announced it received a Complete Response Letter from the FDA for its New Drug Application, meaning the application cannot be approved in its current form.
Why did the FDA reject the cytisinicline application?
The FDA did not cite any problem with the drug's clinical efficacy or safety. It cited manufacturing-related observations from a cGMP inspection of a third-party facility that received an "Official Action Indicated" classification for general compliance matters unrelated to cytisinicline itself, and it noted that final product labeling was not completed by the FDA's action date.
What is a Complete Response Letter?
A Complete Response Letter (CRL) is the FDA's formal notice that a drug application cannot be approved as submitted. It is not necessarily a rejection of the drug's effectiveness or safety — a CRL can be issued for administrative reasons like manufacturing-facility compliance or incomplete labeling, and companies commonly resubmit and later gain approval.
When might cytisinicline get approved?
Achieve Life Sciences has said it intends to resubmit its NDA in Q4 2026, naming Adare as its primary manufacturing partner, and has cited potential FDA approval in the first half of 2027 followed by a US commercial launch. These are the company's stated plans, not a guarantee.
What is cytisinicline?
It's a plant-derived compound that has been used in some countries as a smoking-cessation aid. It is related to, but distinct from, varenicline (Chantix/Champix) — both act on similar nicotinic receptors but are different molecules with separate regulatory histories.
What can I do to quit smoking while cytisinicline isn't yet approved?
You don't need to wait on any pending drug. Talk to a doctor about nicotine replacement therapy or other already-approved prescription options, call a free quitline (1-800-QUIT-NOW in the US), or use a behavioral approach such as a planned taper to a quit date, which is the method apps like NOPE are built around.
